nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—CYP1A2—Pentoxifylline—systemic scleroderma	0.149	0.512	CbGbCtD
Rasagiline—CYP1A2—Leflunomide—systemic scleroderma	0.142	0.488	CbGbCtD
Rasagiline—BCL2—connective tissue—systemic scleroderma	0.00393	0.173	CbGeAlD
Rasagiline—BCL2—smooth muscle tissue—systemic scleroderma	0.0036	0.158	CbGeAlD
Rasagiline—BCL2—skin of body—systemic scleroderma	0.00355	0.156	CbGeAlD
Rasagiline—BCL2—digestive system—systemic scleroderma	0.00284	0.125	CbGeAlD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—TOP1—systemic scleroderma	0.00262	0.0789	CbGpPWpGaD
Rasagiline—MAOB—Alpha-synuclein signaling—BLK—systemic scleroderma	0.0024	0.0722	CbGpPWpGaD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—CD247—systemic scleroderma	0.0024	0.0721	CbGpPWpGaD
Rasagiline—BCL2—lung—systemic scleroderma	0.00237	0.104	CbGeAlD
Rasagiline—MAOB—connective tissue—systemic scleroderma	0.00164	0.0719	CbGeAlD
Rasagiline—BCL2—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—TNFAIP3—systemic scleroderma	0.00161	0.0484	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—COL1A2—systemic scleroderma	0.00157	0.0473	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—IRF8—systemic scleroderma	0.00143	0.043	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—GDF15—systemic scleroderma	0.00128	0.0384	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.00125	0.0376	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—IRF5—systemic scleroderma	0.00119	0.0357	CbGpPWpGaD
Rasagiline—MAOB—digestive system—systemic scleroderma	0.00118	0.0519	CbGeAlD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—IL1A—systemic scleroderma	0.00117	0.0353	CbGpPWpGaD
Rasagiline—MAOB—tendon—systemic scleroderma	0.00113	0.0494	CbGeAlD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.00107	0.0323	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000996	0.03	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IRF5—systemic scleroderma	0.000993	0.0299	CbGpPWpGaD
Rasagiline—MAOB—lung—systemic scleroderma	0.000988	0.0434	CbGeAlD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—BLK—systemic scleroderma	0.000985	0.0296	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—MMP1—systemic scleroderma	0.000954	0.0287	CbGpPWpGaD
Rasagiline—CYP1A2—digestive system—systemic scleroderma	0.000842	0.037	CbGeAlD
Rasagiline—BCL2—Direct p53 effectors—IRF5—systemic scleroderma	0.000789	0.0238	CbGpPWpGaD
Rasagiline—CYP1A2—lung—systemic scleroderma	0.000703	0.0309	CbGeAlD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—systemic scleroderma	0.000697	0.021	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—RHOB—systemic scleroderma	0.00069	0.0208	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—COL1A2—systemic scleroderma	0.00065	0.0196	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—ITGAM—systemic scleroderma	0.000591	0.0178	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—MMP2—systemic scleroderma	0.000584	0.0176	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.000563	0.0169	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—BLK—systemic scleroderma	0.000547	0.0165	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—TGFB1—systemic scleroderma	0.000457	0.0138	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—TGFB1—systemic scleroderma	0.00042	0.0126	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.000383	0.0115	CbGpPWpGaD
Rasagiline—CYP1A2—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000377	0.0114	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000356	0.0107	CbGpPWpGaD
Rasagiline—Body temperature increased—Azathioprine—systemic scleroderma	0.00031	0.000474	CcSEcCtD
Rasagiline—Skin disorder—Lisinopril—systemic scleroderma	0.000309	0.000472	CcSEcCtD
Rasagiline—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000308	0.000471	CcSEcCtD
Rasagiline—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000307	0.00047	CcSEcCtD
Rasagiline—Diarrhoea—Captopril—systemic scleroderma	0.000307	0.00047	CcSEcCtD
Rasagiline—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000307	0.000469	CcSEcCtD
Rasagiline—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000307	0.000469	CcSEcCtD
Rasagiline—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000306	0.000468	CcSEcCtD
Rasagiline—Erectile dysfunction—Prednisone—systemic scleroderma	0.000306	0.000468	CcSEcCtD
Rasagiline—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000305	0.000467	CcSEcCtD
Rasagiline—Feeling abnormal—Leflunomide—systemic scleroderma	0.000305	0.000466	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000305	0.000466	CcSEcCtD
Rasagiline—Mood swings—Methotrexate—systemic scleroderma	0.000304	0.000465	CcSEcCtD
Rasagiline—Nausea—Mometasone—systemic scleroderma	0.000303	0.000464	CcSEcCtD
Rasagiline—Anorexia—Lisinopril—systemic scleroderma	0.000303	0.000463	CcSEcCtD
Rasagiline—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000302	0.000463	CcSEcCtD
Rasagiline—Ataxia—Methotrexate—systemic scleroderma	0.000302	0.000462	CcSEcCtD
Rasagiline—Constipation—Mycophenolic acid—systemic scleroderma	0.000302	0.000462	CcSEcCtD
Rasagiline—Weight decreased—Prednisone—systemic scleroderma	0.0003	0.000459	CcSEcCtD
Rasagiline—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.0003	0.000459	CcSEcCtD
Rasagiline—Cough—Mycophenolate mofetil—systemic scleroderma	0.000298	0.000455	CcSEcCtD
Rasagiline—Hypotension—Lisinopril—systemic scleroderma	0.000297	0.000454	CcSEcCtD
Rasagiline—Dizziness—Captopril—systemic scleroderma	0.000297	0.000454	CcSEcCtD
Rasagiline—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000296	0.000453	CcSEcCtD
Rasagiline—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000296	0.000452	CcSEcCtD
Rasagiline—Depression—Prednisone—systemic scleroderma	0.000295	0.000451	CcSEcCtD
Rasagiline—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000295	0.000451	CcSEcCtD
Rasagiline—Urticaria—Leflunomide—systemic scleroderma	0.000294	0.00045	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	0.000293	0.00883	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—MMP2—systemic scleroderma	0.000292	0.0088	CbGpPWpGaD
Rasagiline—Body temperature increased—Leflunomide—systemic scleroderma	0.000292	0.000447	CcSEcCtD
Rasagiline—Abdominal pain—Leflunomide—systemic scleroderma	0.000292	0.000447	CcSEcCtD
Rasagiline—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000292	0.000446	CcSEcCtD
Rasagiline—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000291	0.000445	CcSEcCtD
Rasagiline—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.00029	0.000444	CcSEcCtD
Rasagiline—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00029	0.000444	CcSEcCtD
Rasagiline—Myocardial infarction—Prednisone—systemic scleroderma	0.00029	0.000444	CcSEcCtD
Rasagiline—Neuropathy peripheral—Prednisone—systemic scleroderma	0.00029	0.000444	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00029	0.000443	CcSEcCtD
Rasagiline—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000289	0.000443	CcSEcCtD
Rasagiline—Hypersensitivity—Azathioprine—systemic scleroderma	0.000289	0.000441	CcSEcCtD
Rasagiline—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000289	0.000441	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000288	0.000441	CcSEcCtD
Rasagiline—Insomnia—Lisinopril—systemic scleroderma	0.000287	0.00044	CcSEcCtD
Rasagiline—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000287	0.000439	CcSEcCtD
Rasagiline—Paraesthesia—Lisinopril—systemic scleroderma	0.000285	0.000437	CcSEcCtD
Rasagiline—Vomiting—Captopril—systemic scleroderma	0.000285	0.000437	CcSEcCtD
Rasagiline—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000284	0.000435	CcSEcCtD
Rasagiline—Dyspnoea—Lisinopril—systemic scleroderma	0.000283	0.000433	CcSEcCtD
Rasagiline—Rash—Captopril—systemic scleroderma	0.000283	0.000433	CcSEcCtD
Rasagiline—Dermatitis—Captopril—systemic scleroderma	0.000283	0.000432	CcSEcCtD
Rasagiline—Somnolence—Lisinopril—systemic scleroderma	0.000283	0.000432	CcSEcCtD
Rasagiline—Headache—Captopril—systemic scleroderma	0.000281	0.00043	CcSEcCtD
Rasagiline—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000281	0.00043	CcSEcCtD
Rasagiline—Dyspepsia—Lisinopril—systemic scleroderma	0.00028	0.000428	CcSEcCtD
Rasagiline—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000279	0.000427	CcSEcCtD
Rasagiline—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000279	0.000427	CcSEcCtD
Rasagiline—Asthma—Methotrexate—systemic scleroderma	0.000277	0.000424	CcSEcCtD
Rasagiline—Infection—Mycophenolate mofetil—systemic scleroderma	0.000277	0.000423	CcSEcCtD
Rasagiline—Decreased appetite—Lisinopril—systemic scleroderma	0.000276	0.000423	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000274	0.00042	CcSEcCtD
Rasagiline—Shock—Mycophenolate mofetil—systemic scleroderma	0.000274	0.000419	CcSEcCtD
Rasagiline—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000273	0.000418	CcSEcCtD
Rasagiline—Hypersensitivity—Leflunomide—systemic scleroderma	0.000272	0.000417	CcSEcCtD
Rasagiline—Constipation—Lisinopril—systemic scleroderma	0.000272	0.000416	CcSEcCtD
Rasagiline—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00027	0.000414	CcSEcCtD
Rasagiline—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000269	0.000412	CcSEcCtD
Rasagiline—Diarrhoea—Azathioprine—systemic scleroderma	0.000268	0.00041	CcSEcCtD
Rasagiline—Haemoglobin—Prednisone—systemic scleroderma	0.000267	0.000409	CcSEcCtD
Rasagiline—Nausea—Captopril—systemic scleroderma	0.000267	0.000408	CcSEcCtD
Rasagiline—Haemorrhage—Prednisone—systemic scleroderma	0.000266	0.000406	CcSEcCtD
Rasagiline—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000265	0.000406	CcSEcCtD
Rasagiline—Asthenia—Leflunomide—systemic scleroderma	0.000265	0.000406	CcSEcCtD
Rasagiline—Hallucination—Prednisone—systemic scleroderma	0.000264	0.000404	CcSEcCtD
Rasagiline—Feeling abnormal—Lisinopril—systemic scleroderma	0.000262	0.000401	CcSEcCtD
Rasagiline—Pruritus—Leflunomide—systemic scleroderma	0.000262	0.0004	CcSEcCtD
Rasagiline—Connective tissue disorder—Prednisone—systemic scleroderma	0.000261	0.000399	CcSEcCtD
Rasagiline—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.00026	0.000398	CcSEcCtD
Rasagiline—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00026	0.000398	CcSEcCtD
Rasagiline—Dysuria—Methotrexate—systemic scleroderma	0.000259	0.000397	CcSEcCtD
Rasagiline—Dizziness—Azathioprine—systemic scleroderma	0.000259	0.000396	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000258	0.000394	CcSEcCtD
Rasagiline—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000255	0.000391	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000254	0.000388	CcSEcCtD
Rasagiline—BCL2—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	0.000253	0.00763	CbGpPWpGaD
Rasagiline—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000253	0.000387	CcSEcCtD
Rasagiline—Asthenia—Mycophenolic acid—systemic scleroderma	0.000253	0.000387	CcSEcCtD
Rasagiline—Diarrhoea—Leflunomide—systemic scleroderma	0.000253	0.000387	CcSEcCtD
Rasagiline—Urticaria—Lisinopril—systemic scleroderma	0.000252	0.000386	CcSEcCtD
Rasagiline—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000252	0.000385	CcSEcCtD
Rasagiline—Body temperature increased—Lisinopril—systemic scleroderma	0.000251	0.000384	CcSEcCtD
Rasagiline—Abdominal pain—Lisinopril—systemic scleroderma	0.000251	0.000384	CcSEcCtD
Rasagiline—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00025	0.000383	CcSEcCtD
Rasagiline—Pruritus—Mycophenolic acid—systemic scleroderma	0.00025	0.000382	CcSEcCtD
Rasagiline—Vomiting—Azathioprine—systemic scleroderma	0.000249	0.000381	CcSEcCtD
Rasagiline—Eye disorder—Prednisone—systemic scleroderma	0.000248	0.00038	CcSEcCtD
Rasagiline—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000248	0.00038	CcSEcCtD
Rasagiline—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000248	0.000379	CcSEcCtD
Rasagiline—Infestation—Methotrexate—systemic scleroderma	0.000247	0.000378	CcSEcCtD
Rasagiline—Infestation NOS—Methotrexate—systemic scleroderma	0.000247	0.000378	CcSEcCtD
Rasagiline—Rash—Azathioprine—systemic scleroderma	0.000247	0.000378	CcSEcCtD
Rasagiline—Dermatitis—Azathioprine—systemic scleroderma	0.000247	0.000377	CcSEcCtD
Rasagiline—Depression—Methotrexate—systemic scleroderma	0.000247	0.000377	CcSEcCtD
Rasagiline—Headache—Azathioprine—systemic scleroderma	0.000245	0.000375	CcSEcCtD
Rasagiline—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000245	0.000375	CcSEcCtD
Rasagiline—Dizziness—Leflunomide—systemic scleroderma	0.000245	0.000374	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CD247—systemic scleroderma	0.000243	0.00731	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—ITGAM—systemic scleroderma	0.000243	0.00731	CbGpPWpGaD
Rasagiline—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000242	0.00037	CcSEcCtD
Rasagiline—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000241	0.000369	CcSEcCtD
Rasagiline—Stomatitis—Methotrexate—systemic scleroderma	0.000241	0.000369	CcSEcCtD
Rasagiline—Angiopathy—Prednisone—systemic scleroderma	0.000241	0.000369	CcSEcCtD
Rasagiline—Conjunctivitis—Methotrexate—systemic scleroderma	0.00024	0.000368	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00024	0.000368	CcSEcCtD
Rasagiline—Immune system disorder—Prednisone—systemic scleroderma	0.00024	0.000367	CcSEcCtD
Rasagiline—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000238	0.000364	CcSEcCtD
Rasagiline—Sweating—Methotrexate—systemic scleroderma	0.000237	0.000363	CcSEcCtD
Rasagiline—Haematuria—Methotrexate—systemic scleroderma	0.000236	0.000361	CcSEcCtD
Rasagiline—Vomiting—Leflunomide—systemic scleroderma	0.000235	0.00036	CcSEcCtD
Rasagiline—Alopecia—Prednisone—systemic scleroderma	0.000235	0.000359	CcSEcCtD
Rasagiline—Hypersensitivity—Lisinopril—systemic scleroderma	0.000234	0.000358	CcSEcCtD
Rasagiline—Dizziness—Mycophenolic acid—systemic scleroderma	0.000233	0.000357	CcSEcCtD
Rasagiline—Epistaxis—Methotrexate—systemic scleroderma	0.000233	0.000357	CcSEcCtD
Rasagiline—Rash—Leflunomide—systemic scleroderma	0.000233	0.000357	CcSEcCtD
Rasagiline—Dermatitis—Leflunomide—systemic scleroderma	0.000233	0.000356	CcSEcCtD
Rasagiline—Mental disorder—Prednisone—systemic scleroderma	0.000233	0.000356	CcSEcCtD
Rasagiline—Nausea—Azathioprine—systemic scleroderma	0.000233	0.000356	CcSEcCtD
Rasagiline—Headache—Leflunomide—systemic scleroderma	0.000232	0.000354	CcSEcCtD
Rasagiline—Malnutrition—Prednisone—systemic scleroderma	0.000231	0.000354	CcSEcCtD
Rasagiline—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000229	0.000351	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	0.000228	0.00686	CbGpPWpGaD
Rasagiline—Asthenia—Lisinopril—systemic scleroderma	0.000228	0.000349	CcSEcCtD
Rasagiline—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000228	0.000348	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—TNFAIP3—systemic scleroderma	0.000227	0.00685	CbGpPWpGaD
Rasagiline—Pruritus—Lisinopril—systemic scleroderma	0.000225	0.000344	CcSEcCtD
Rasagiline—Vomiting—Mycophenolic acid—systemic scleroderma	0.000224	0.000343	CcSEcCtD
Rasagiline—Haemoglobin—Methotrexate—systemic scleroderma	0.000223	0.000341	CcSEcCtD
Rasagiline—Rash—Mycophenolic acid—systemic scleroderma	0.000222	0.00034	CcSEcCtD
Rasagiline—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000222	0.00034	CcSEcCtD
Rasagiline—Haemorrhage—Methotrexate—systemic scleroderma	0.000222	0.00034	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TGFB1—systemic scleroderma	0.000221	0.00666	CbGpPWpGaD
Rasagiline—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000221	0.000338	CcSEcCtD
Rasagiline—Headache—Mycophenolic acid—systemic scleroderma	0.000221	0.000338	CcSEcCtD
Rasagiline—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00022	0.000337	CcSEcCtD
Rasagiline—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00022	0.000337	CcSEcCtD
Rasagiline—Nausea—Leflunomide—systemic scleroderma	0.00022	0.000336	CcSEcCtD
Rasagiline—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000219	0.000335	CcSEcCtD
Rasagiline—Urethral disorder—Methotrexate—systemic scleroderma	0.000218	0.000333	CcSEcCtD
Rasagiline—Diarrhoea—Lisinopril—systemic scleroderma	0.000217	0.000333	CcSEcCtD
Rasagiline—Ill-defined disorder—Prednisone—systemic scleroderma	0.000215	0.000328	CcSEcCtD
Rasagiline—Anaemia—Prednisone—systemic scleroderma	0.000214	0.000327	CcSEcCtD
Rasagiline—Agitation—Prednisone—systemic scleroderma	0.000213	0.000325	CcSEcCtD
Rasagiline—Dizziness—Lisinopril—systemic scleroderma	0.00021	0.000322	CcSEcCtD
Rasagiline—Nausea—Mycophenolic acid—systemic scleroderma	0.00021	0.000321	CcSEcCtD
Rasagiline—Malaise—Prednisone—systemic scleroderma	0.000209	0.000319	CcSEcCtD
Rasagiline—Vertigo—Prednisone—systemic scleroderma	0.000208	0.000318	CcSEcCtD
Rasagiline—Eye disorder—Methotrexate—systemic scleroderma	0.000207	0.000317	CcSEcCtD
Rasagiline—Syncope—Prednisone—systemic scleroderma	0.000207	0.000317	CcSEcCtD
Rasagiline—Cardiac disorder—Methotrexate—systemic scleroderma	0.000206	0.000315	CcSEcCtD
Rasagiline—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000205	0.000314	CcSEcCtD
Rasagiline—Loss of consciousness—Prednisone—systemic scleroderma	0.000203	0.000311	CcSEcCtD
Rasagiline—Vomiting—Lisinopril—systemic scleroderma	0.000202	0.000309	CcSEcCtD
Rasagiline—Angiopathy—Methotrexate—systemic scleroderma	0.000201	0.000308	CcSEcCtD
Rasagiline—Immune system disorder—Methotrexate—systemic scleroderma	0.000201	0.000307	CcSEcCtD
Rasagiline—Rash—Lisinopril—systemic scleroderma	0.0002	0.000307	CcSEcCtD
Rasagiline—Convulsion—Prednisone—systemic scleroderma	0.0002	0.000307	CcSEcCtD
Rasagiline—Dermatitis—Lisinopril—systemic scleroderma	0.0002	0.000306	CcSEcCtD
Rasagiline—Mediastinal disorder—Methotrexate—systemic scleroderma	0.0002	0.000306	CcSEcCtD
Rasagiline—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.0002	0.000306	CcSEcCtD
Rasagiline—Hypertension—Prednisone—systemic scleroderma	0.0002	0.000305	CcSEcCtD
Rasagiline—Chills—Methotrexate—systemic scleroderma	0.000199	0.000305	CcSEcCtD
Rasagiline—Headache—Lisinopril—systemic scleroderma	0.000199	0.000305	CcSEcCtD
Rasagiline—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000197	0.000301	CcSEcCtD
Rasagiline—Arthralgia—Prednisone—systemic scleroderma	0.000197	0.000301	CcSEcCtD
Rasagiline—Anxiety—Prednisone—systemic scleroderma	0.000196	0.0003	CcSEcCtD
Rasagiline—Alopecia—Methotrexate—systemic scleroderma	0.000196	0.0003	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000196	0.000299	CcSEcCtD
Rasagiline—Discomfort—Prednisone—systemic scleroderma	0.000195	0.000298	CcSEcCtD
Rasagiline—Mental disorder—Methotrexate—systemic scleroderma	0.000195	0.000298	CcSEcCtD
Rasagiline—Malnutrition—Methotrexate—systemic scleroderma	0.000193	0.000296	CcSEcCtD
Rasagiline—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000291	CcSEcCtD
Rasagiline—Dysgeusia—Methotrexate—systemic scleroderma	0.000189	0.00029	CcSEcCtD
Rasagiline—Nausea—Lisinopril—systemic scleroderma	0.000189	0.000289	CcSEcCtD
Rasagiline—Infection—Prednisone—systemic scleroderma	0.000188	0.000287	CcSEcCtD
Rasagiline—Back pain—Methotrexate—systemic scleroderma	0.000187	0.000286	CcSEcCtD
Rasagiline—Shock—Prednisone—systemic scleroderma	0.000186	0.000284	CcSEcCtD
Rasagiline—Nervous system disorder—Prednisone—systemic scleroderma	0.000185	0.000283	CcSEcCtD
Rasagiline—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000184	0.000282	CcSEcCtD
Rasagiline—Skin disorder—Prednisone—systemic scleroderma	0.000183	0.00028	CcSEcCtD
Rasagiline—Hyperhidrosis—Prednisone—systemic scleroderma	0.000182	0.000279	CcSEcCtD
Rasagiline—Anorexia—Prednisone—systemic scleroderma	0.00018	0.000275	CcSEcCtD
Rasagiline—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000179	0.000274	CcSEcCtD
Rasagiline—Anaemia—Methotrexate—systemic scleroderma	0.000179	0.000273	CcSEcCtD
Rasagiline—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000177	0.000271	CcSEcCtD
Rasagiline—Rash—Mycophenolate mofetil—systemic scleroderma	0.000176	0.000269	CcSEcCtD
Rasagiline—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000268	CcSEcCtD
Rasagiline—Headache—Mycophenolate mofetil—systemic scleroderma	0.000174	0.000267	CcSEcCtD
Rasagiline—Malaise—Methotrexate—systemic scleroderma	0.000174	0.000267	CcSEcCtD
Rasagiline—Vertigo—Methotrexate—systemic scleroderma	0.000174	0.000266	CcSEcCtD
Rasagiline—Leukopenia—Methotrexate—systemic scleroderma	0.000173	0.000265	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000172	0.000263	CcSEcCtD
Rasagiline—Insomnia—Prednisone—systemic scleroderma	0.000171	0.000261	CcSEcCtD
Rasagiline—Paraesthesia—Prednisone—systemic scleroderma	0.000169	0.000259	CcSEcCtD
Rasagiline—Cough—Methotrexate—systemic scleroderma	0.000169	0.000258	CcSEcCtD
Rasagiline—Convulsion—Methotrexate—systemic scleroderma	0.000167	0.000256	CcSEcCtD
Rasagiline—Dyspepsia—Prednisone—systemic scleroderma	0.000166	0.000254	CcSEcCtD
Rasagiline—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000165	0.000253	CcSEcCtD
Rasagiline—Arthralgia—Methotrexate—systemic scleroderma	0.000165	0.000252	CcSEcCtD
Rasagiline—Chest pain—Methotrexate—systemic scleroderma	0.000165	0.000252	CcSEcCtD
Rasagiline—Decreased appetite—Prednisone—systemic scleroderma	0.000164	0.000251	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000163	0.00025	CcSEcCtD
Rasagiline—Discomfort—Methotrexate—systemic scleroderma	0.000163	0.000249	CcSEcCtD
Rasagiline—Constipation—Prednisone—systemic scleroderma	0.000161	0.000247	CcSEcCtD
Rasagiline—Confusional state—Methotrexate—systemic scleroderma	0.000159	0.000243	CcSEcCtD
Rasagiline—Infection—Methotrexate—systemic scleroderma	0.000157	0.00024	CcSEcCtD
Rasagiline—Feeling abnormal—Prednisone—systemic scleroderma	0.000156	0.000238	CcSEcCtD
Rasagiline—Nervous system disorder—Methotrexate—systemic scleroderma	0.000155	0.000237	CcSEcCtD
Rasagiline—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000154	0.000236	CcSEcCtD
Rasagiline—Skin disorder—Methotrexate—systemic scleroderma	0.000153	0.000234	CcSEcCtD
Rasagiline—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000152	0.000233	CcSEcCtD
Rasagiline—BCL2—Immune System—CSK—systemic scleroderma	0.00015	0.00453	CbGpPWpGaD
Rasagiline—Anorexia—Methotrexate—systemic scleroderma	0.00015	0.00023	CcSEcCtD
Rasagiline—Urticaria—Prednisone—systemic scleroderma	0.00015	0.000229	CcSEcCtD
Rasagiline—Body temperature increased—Prednisone—systemic scleroderma	0.000149	0.000228	CcSEcCtD
Rasagiline—Abdominal pain—Prednisone—systemic scleroderma	0.000149	0.000228	CcSEcCtD
Rasagiline—BCL2—Immune System—IRF5—systemic scleroderma	0.000148	0.00446	CbGpPWpGaD
Rasagiline—Hypotension—Methotrexate—systemic scleroderma	0.000147	0.000226	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000144	0.00022	CcSEcCtD
Rasagiline—Insomnia—Methotrexate—systemic scleroderma	0.000143	0.000218	CcSEcCtD
Rasagiline—Paraesthesia—Methotrexate—systemic scleroderma	0.000142	0.000217	CcSEcCtD
Rasagiline—BCL2—Immune System—IRF8—systemic scleroderma	0.000141	0.00426	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ITGAM—systemic scleroderma	0.000141	0.00426	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD247—systemic scleroderma	0.000141	0.00426	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000141	0.00425	CbGpPWpGaD
Rasagiline—Dyspnoea—Methotrexate—systemic scleroderma	0.000141	0.000215	CcSEcCtD
Rasagiline—Somnolence—Methotrexate—systemic scleroderma	0.00014	0.000215	CcSEcCtD
Rasagiline—Hypersensitivity—Prednisone—systemic scleroderma	0.000139	0.000213	CcSEcCtD
Rasagiline—Dyspepsia—Methotrexate—systemic scleroderma	0.000139	0.000212	CcSEcCtD
Rasagiline—Decreased appetite—Methotrexate—systemic scleroderma	0.000137	0.00021	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000136	0.000208	CcSEcCtD
Rasagiline—Asthenia—Prednisone—systemic scleroderma	0.000135	0.000207	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000135	0.00407	CbGpPWpGaD
Rasagiline—Pruritus—Prednisone—systemic scleroderma	0.000134	0.000204	CcSEcCtD
Rasagiline—BCL2—Immune System—TNFAIP3—systemic scleroderma	0.000132	0.00399	CbGpPWpGaD
Rasagiline—BCL2—Immune System—BLK—systemic scleroderma	0.000131	0.00394	CbGpPWpGaD
Rasagiline—Feeling abnormal—Methotrexate—systemic scleroderma	0.00013	0.000199	CcSEcCtD
Rasagiline—Diarrhoea—Prednisone—systemic scleroderma	0.000129	0.000198	CcSEcCtD
Rasagiline—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000129	0.000197	CcSEcCtD
Rasagiline—Urticaria—Methotrexate—systemic scleroderma	0.000125	0.000192	CcSEcCtD
Rasagiline—Dizziness—Prednisone—systemic scleroderma	0.000125	0.000191	CcSEcCtD
Rasagiline—Abdominal pain—Methotrexate—systemic scleroderma	0.000125	0.000191	CcSEcCtD
Rasagiline—Body temperature increased—Methotrexate—systemic scleroderma	0.000125	0.000191	CcSEcCtD
Rasagiline—MAOB—Metabolism—HSPG2—systemic scleroderma	0.000124	0.00373	CbGpPWpGaD
Rasagiline—Vomiting—Prednisone—systemic scleroderma	0.00012	0.000184	CcSEcCtD
Rasagiline—Rash—Prednisone—systemic scleroderma	0.000119	0.000182	CcSEcCtD
Rasagiline—Dermatitis—Prednisone—systemic scleroderma	0.000119	0.000182	CcSEcCtD
Rasagiline—Headache—Prednisone—systemic scleroderma	0.000118	0.000181	CcSEcCtD
Rasagiline—Hypersensitivity—Methotrexate—systemic scleroderma	0.000116	0.000178	CcSEcCtD
Rasagiline—Asthenia—Methotrexate—systemic scleroderma	0.000113	0.000173	CcSEcCtD
Rasagiline—Nausea—Prednisone—systemic scleroderma	0.000112	0.000172	CcSEcCtD
Rasagiline—Pruritus—Methotrexate—systemic scleroderma	0.000112	0.000171	CcSEcCtD
Rasagiline—Diarrhoea—Methotrexate—systemic scleroderma	0.000108	0.000165	CcSEcCtD
Rasagiline—BCL2—Immune System—CTLA4—systemic scleroderma	0.000107	0.00323	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000105	0.00316	CbGpPWpGaD
Rasagiline—Dizziness—Methotrexate—systemic scleroderma	0.000104	0.00016	CcSEcCtD
Rasagiline—Vomiting—Methotrexate—systemic scleroderma	0.0001	0.000153	CcSEcCtD
Rasagiline—Rash—Methotrexate—systemic scleroderma	9.95e-05	0.000152	CcSEcCtD
Rasagiline—Dermatitis—Methotrexate—systemic scleroderma	9.94e-05	0.000152	CcSEcCtD
Rasagiline—Headache—Methotrexate—systemic scleroderma	9.88e-05	0.000151	CcSEcCtD
Rasagiline—MAOB—Metabolism—CTGF—systemic scleroderma	9.4e-05	0.00283	CbGpPWpGaD
Rasagiline—Nausea—Methotrexate—systemic scleroderma	9.37e-05	0.000143	CcSEcCtD
Rasagiline—BCL2—Immune System—HLA-DQB1—systemic scleroderma	8.83e-05	0.00266	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL1A—systemic scleroderma	8.39e-05	0.00252	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD40LG—systemic scleroderma	8.34e-05	0.00251	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.44e-05	0.00194	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.88e-05	0.00147	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL1B—systemic scleroderma	4.37e-05	0.00132	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NOS3—systemic scleroderma	4.09e-05	0.00123	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HSPG2—systemic scleroderma	2.87e-05	0.000864	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CTGF—systemic scleroderma	2.17e-05	0.000655	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NOS3—systemic scleroderma	9.47e-06	0.000285	CbGpPWpGaD
